share_log

Earnings Call Summary | Tivic Health Systems(TIVC.US) Q1 2024 Earnings Conference

Earnings Call Summary | Tivic Health Systems(TIVC.US) Q1 2024 Earnings Conference

業績電話會議摘要 | Tivic Health Systems (TIVC.US) 2024 年第一季度業績會議
富途資訊 ·  05/16 09:15  · 電話會議

The following is a summary of the Tivic Health Systems, Inc. (TIVC) Q1 2024 Earnings Call Transcript:

以下是Tivic Health Systems, Inc.(TIVC)2024年第一季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • Tivic Health reported Q1 revenue of $334,000, a decrease of 11.2% from the same quarter last year primarily due to a significant decrease in unit sales resulting from a price increase of their product, ClearUp.

  • Despite the drop in unit sales, the gross profit for the first quarter increased by 48% due to the ClearUP price increase and reduction in cost per unit.

  • The company's total operating expenses for the first quarter dropped by 26% due to lower staff consulting, decreased professional fees, and reduced general/administrative expenses.

  • Tivic Health公佈的第一季度收入爲33.4萬美元,比去年同期下降11.2%,這主要是由於其產品ClearUp的價格上漲導致單位銷售額大幅下降。

  • 儘管單位銷售額下降,但由於ClearUp價格的上漲和單位成本的降低,第一季度的毛利增長了48%。

  • 由於員工諮詢減少、專業費用減少以及一般/管理費用減少,該公司第一季度的總運營支出下降了26%。

Business Progress:

業務進展:

  • Tivic established a limited exclusive distribution agreement with McKesson for the distribution of ClearUP and initiated the restructuring of their supply chain to be better aligned with short-term business needs.

  • Tivic successfully launched a new version of ClearUP that rectified a technical issue and completed a pilot clinical study for a novel form of noninvasive vagus nerve stimulation (VNS) with Feinstein Institutes for Medical Research.

  • After the VNS program announcement, the company closed a $4 million financing round. The funds are expected to be used as working capital, which includes advancing the next phase of the VNS clinical program.

  • Tivic與McKesson簽訂了分銷ClearUp的有限獨家分銷協議,並啓動了供應鏈的重組,以更好地適應短期業務需求。

  • Tivic成功推出了新版本的ClearUp,該版本糾正了一個技術問題,並與費恩斯坦醫學研究所完成了對一種新型無創迷走神經刺激(VNS)的試點臨床研究。

  • VNS計劃宣佈後,該公司完成了400萬美元的融資。這些資金預計將用作營運資金,其中包括推進VNS臨床計劃的下一階段。

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論